Archemix gains access to Lilly IP, while Lilly will assess aptamer targets for potential license.
Archemix inked an agreement with Eli Lilly for aptamer-based therapeutic R&D evaluation and access to intellectual property (IP). The deal enables Archemix to license certain IP rights from Lilly.
“This agreement also supports our strategy to further strengthen Archemix’ position of consolidating all of the significant intellectual property related to aptamer therapeutics,” notes Errol De Souza, Ph.D., president and CEO of Archemix.
In return, Lilly has an option to conduct R&D assessment of aptamers for certain drug targets. Lilly also retains an option to enter into an exclusive license with Archemix for up to two of the aptamer targets.
Aptamers are synthetically derived oligonucleotides that bind to protein targets with high affinity and specificity and can be designed to have a specified duration of action.
Archemix has licensed its IP to various companies including Pfizer, Merck Serono, NascaCell, and Ribomics.
